Pulmonary Arterial Hypertension Pah Market

DelveInsight's "Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pulmonary Arterial Hypertension (PAH) , historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension (PAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pulmonary Arterial Hypertension (PAH) market report provides current treatment practices, emerging drugs, Pulmonary Arterial Hypertension (PAH) market share of the individual therapies, current and forecasted Pulmonary Arterial Hypertension (PAH) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Pulmonary Arterial Hypertension (PAH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Pulmonary Arterial Hypertension (PAH) Disease Understanding and Treatment Algorithm

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.


The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the PAH by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe and Japan. 


Pulmonary Arterial Hypertension (PAH) Epidemiology  

The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.


According to DelveInsight, the total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017.


Pulmonary Arterial Hypertension (PAH) Drug Chapters

This segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


The therapeutic market of Pulmonary Arterial Hypertension is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the treatment of Pulmonary Arterial Hypertension. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of PAH. Letairis\Volibris (GlaxoSmithKline plc\Gilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the treatment of Pulmonary Arterial Hypertension. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodeling of blood vessels. 


Pulmonary Arterial Hypertension (PAH) Market Outlook

The Pulmonary Arterial Hypertension market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 


This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the market of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017, and is expected to increase during the course of the study period (2017–2030).


Among the 7MM, the United States accounts for the largest market size of PAH, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


Pulmonary Arterial Hypertension (PAH) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension (PAH) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Pulmonary Arterial Hypertension (PAH) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Pulmonary Arterial Hypertension (PAH) Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Pulmonary Arterial Hypertension (PAH) key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Pulmonary Arterial Hypertension (PAH) emerging therapies.


Reimbursement Scenario in Pulmonary Arterial Hypertension (PAH)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Pulmonary Arterial Hypertension (PAH) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Pulmonary Arterial Hypertension (PAH) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Pulmonary Arterial Hypertension (PAH) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Pulmonary Arterial Hypertension (PAH) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Pulmonary Arterial Hypertension (PAH) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Pulmonary Arterial Hypertension (PAH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Pulmonary Arterial Hypertension (PAH) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pulmonary Arterial Hypertension (PAH) market


Report Highlights

  • In the coming years, Pulmonary Arterial Hypertension (PAH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension (PAH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Pulmonary Arterial Hypertension (PAH) . Launch of emerging therapies will significantly impact the Pulmonary Arterial Hypertension (PAH) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Pulmonary Arterial Hypertension (PAH)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Pulmonary Arterial Hypertension (PAH) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pulmonary Arterial Hypertension (PAH) Pipeline Analysis
  • Pulmonary Arterial Hypertension (PAH) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Pulmonary Arterial Hypertension (PAH) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Pulmonary Arterial Hypertension (PAH) Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Pulmonary Arterial Hypertension (PAH) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Pulmonary Arterial Hypertension (PAH) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Pulmonary Arterial Hypertension (PAH) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Pulmonary Arterial Hypertension (PAH) market size during the forecast period (2017-2030)?
  • At what CAGR, the Pulmonary Arterial Hypertension (PAH) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Pulmonary Arterial Hypertension (PAH) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Pulmonary Arterial Hypertension (PAH) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Pulmonary Arterial Hypertension (PAH) ?
  • What is the historical Pulmonary Arterial Hypertension (PAH) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Pulmonary Arterial Hypertension (PAH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Pulmonary Arterial Hypertension (PAH) ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Pulmonary Arterial Hypertension (PAH) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Pulmonary Arterial Hypertension (PAH) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Pulmonary Arterial Hypertension (PAH) in the USA, Europe, and Japan?
  • What are the Pulmonary Arterial Hypertension (PAH) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Pulmonary Arterial Hypertension (PAH) ?
  • How many therapies are developed by each company for Pulmonary Arterial Hypertension (PAH) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Pulmonary Arterial Hypertension (PAH) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension (PAH) therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Pulmonary Arterial Hypertension (PAH) and their status?
  • What are the key designations that have been granted for the emerging therapies for Pulmonary Arterial Hypertension (PAH) ?
  • What are the global historical and forecasted market of Pulmonary Arterial Hypertension (PAH) ?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market
  • To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market
  • To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market


What is Pulmonary Arterial Hypertension (PAH)?

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs.


What was the Pulmonary Arterial Hypertension (PAH) prevalent population in the 7 major markets?

According to DelveInsight’s estimates, in 2017 the total prevalent cases of Pulmonary Arterial Hypertension were 70,774 in the seven major markets.


Which geography accounted for the largest Pulmonary Arterial Hypertension (PAH) market size?

The Unites States accounted for the largest Pulmonary Arterial Hypertension (PAH) market size in the 7MM.


What are the emerging therapies in the Pulmonary Arterial Hypertension (PAH) market?

Increase in the growth of the market is expected due to upcoming Pulmonary Arterial Hypertension (PAH) therapies such as Aurora-GT (United Therapeutics Corp.), Ralinepag (Arena Pharmaceuticals), Rodatristat Ethyl (Altavant Sciences), and Sotatercept (Acceleron Pharma). Launch of the already approved drug, Opsumit (Actelion Pharmaceuticals Ltd.) for the treatment of Pediatric Pulmonary Arterial Hypertension is also believed to create a positive impact on the market size of PAH.


Which are the leading companies in Pulmonary Arterial Hypertension (PAH) market?

Key companies in the Pulmonary Arterial Hypertension (PAH) market are United Therapeutics Corp., Arena Pharmaceuticals, Altavant Sciences, Acceleron Pharma and others.


How is epidemiology segmented for Pulmonary Arterial Hypertension (PAH)?

Pulmonary Arterial Hypertension (PAH) epidemiology is segmented into Prevalent Population, Subtype-Specific Prevalent Population, and Gender-Specific Prevalent Population of PAH in 7MM 2017–2030.

1. Key Insights

2. Executive Summary of Pulmonary Arterial Hypertension

3. SWOT Analysis for Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance

4.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017

4.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030

5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification of Pulmonary Arterial Hypertension (PAH)

5.3.1. WHO classification

5.3.2. Functional Classification of PAH

5.4. Etiology

5.5. Risk factors

5.6. Pathophysiology

5.7. Diagnosis

5.7.1. Diagnostic Guidelines: European Guidelines of PAH

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Population and Forecast Parameters

6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

7.1. The United States

7.1.1. Total Prevalent Patient Population of PAH in the United States

7.1.2. Sub-type Specific Prevalence of PAH in the United States

7.1.3. Gender specific Prevalence of PAH in the United States

7.2. Germany

7.2.1. Total Prevalent Patient Population of PAH in Germany

7.2.2. Sub-type Specific Prevalence of PAH in Germany

7.2.3. Gender specific Prevalence of PAH in Germany

7.3. France

7.3.1. Total Prevalent Patient Population of PAH in France

7.3.2. Sub-type Specific Prevalence of PAH in France

7.3.3. Gender specific Prevalence of PAH in France

7.4. Italy

7.4.1. Total Prevalent Patient Population of PAH in Italy

7.4.2. Sub-type Specific Prevalence of PAH in Italy

7.4.3. Gender specific Prevalence of PAH in Italy

7.5. Spain

7.5.1. Total Prevalent Patient Population of PAH in Spain

7.5.2. Sub-type Specific Prevalence of PAH in Spain

7.5.3. Gender specific Prevalence of PAH in Spain

7.6. The United Kingdom

7.6.1. Total Prevalent Patient Population of PAH in the UK

7.6.2. Sub-type Specific Prevalence of PAH in the UK

7.6.3. Gender specific Prevalence of PAH in the United Kingdom

7.7. Japan

7.7.1. Total Prevalent Patient Population of PAH in Japan

7.7.2. Sub-type Specific Prevalence of PAH in Japan

7.7.3. Gender specific Prevalence of PAH in Japan

8. Treatment Algorithm

8.1. Current Treatment Practices

8.2. Treatment Guidelines

8.2.1. CHEST Guidelines [The United States]

8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

9. Unmet Needs

10. Case Studies

10.1. A Rare Case of Drug Induced PAH

10.2. A Case Report of Unconventional Delivery of Inhaled NO

11. Organizations related with PAH

12. Marketed Drugs

12.1. Approval and Market Presence

13. Marketed Drugs by Companies

13.1. United Therapeutics Corporation

13.2. Johnson & Johnson

13.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.

13.4. Bayer AG

13.5. Pfizer

14. Safety and Efficacy of Marketed Drugs

15. Emerging Therapies

15.1. Emerging Drugs Analysis

15.2. Aurora-GT: United Therapeutics

15.2.1. Other Developmental Activities

15.2.2. Clinical Development

15.2.3. Safety and Efficacy

15.3. Ralinepag: United Therapeutics

15.3.1. Other Developmental Activities

15.3.2. Clinical Development

15.3.3. Safety and Efficacy

15.4. Liquidia Technologies

15.4.1. Other Developmental Activities

15.4.2. Clinical Development

15.4.3. Safety and Efficacy

15.5. Bardoxolone Methyl: Reata Pharmaceuticals

15.5.1. Other Developmental Activities

15.5.2. Clinical Development

15.5.3. Safety and Efficacy

15.6. Rodatristat Ethyl: Altavant Sciences

15.6.1. Other Development Activities

15.6.2. Clinical Development

15.6.3. Safety and Efficacy

15.7. Sotatercept: Acceleron Pharma

15.7.1. Other Developmental Activities

15.7.2. Clinical Development

15.7.3. Safety and Efficacy

15.8. PB1064: PhaseBio Pharmaceuticals

15.8.1. Other Developmental Activities

15.8.2. Clinical Development

15.8.3. Safety and Efficacy

15.9. CXA-10: Complexa

15.9.1. Other Developmental Activities

15.9.2. Clinical Development

15.9.3. Safety and Efficacy

16. Other Promising Candidates

16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies

16.1.1. Other Developmental Activities

16.1.2. Clinical Development

16.1.3. Safety and Efficacy

16.2. RT234: Respira Therapeutics

16.2.1. Other Developmental Activities

16.2.2. Clinical Development

16.2.3. Safety and Efficacy

17. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis

17.1. Key Findings

17.2. Total Market Size of PAH in 7MM

17.3. Market Outlook: 7MM

18. United States

18.1. Total Market size of PAH

18.2. PAH Market Size by Therapies

19. EU5 Countries

19.1. Germany

19.1.1. Total Market size of PAH

19.1.2. PAH Market Size by Therapies

19.2. France

19.2.1. Total Market size of PAH

19.2.2. PAH Market Size by Therapies

19.3. Italy

19.3.1. Total Market size of PAH

19.3.2. PAH Market Size by Therapies

19.4. Spain

19.4.1. Total Market size of PAH

19.4.2. PAH Market Size by Therapies

19.5. United Kingdom

19.5.1. Total Market size of PAH

19.5.2. PAH Market Size by Therapies

20. Japan

20.1. Total Market size of PAH

20.2. PAH Market Size by Therapies

21. Market Drivers

22. Market Barriers

23. Appendix

23.1. Bibliography

23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List Of Tables:

Table 1: Summary of Pulmonary Arterial Hypertension (PAH) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Pulmonary Arterial Hypertension (PAH)

Table 3: Hemodynamic profiles of pulmonary hypertension

Table 4: Total Prevalent Patient Population of PAH in 7MM (2017–2030)

Table 5: Total Prevalent Population of PAH in the United States (2017–2030)

Table 6: Sub-type Specific Prevalence of PAH in the United States (2017–2030)

Table 7: Gender specific Prevalence of PAH in the United States (2017–2030)

Table 8: Total Prevalent Population of PAH in Germany (2017–2030)

Table 9: Sub-type Specific Prevalence of PAH in Germany (2017–2030)

Table 10: Gender specific Prevalence of PAH in Germany (2017–2030)

Table 11: Total Prevalent Population of PAH in France (2017–2030)

Table 12: Sub-type Specific Prevalence of PAH in France (2017–2030)

Table 13: Gender specific Prevalence of PAH in France (2017–2030)

Table 14: Total Prevalent Population of PAH in Italy (2017–2030)

Table 15: Sub-type Specific Prevalence of PAH in Italy (2017–2030)

Table 16: Gender specific Prevalence of PAH in Italy (2017–2030)

Table 17: Total Prevalent Population of PAH in Spain (2017–2030)

Table 18: Sub-type Specific Prevalence of PAH in Italy (2017–2030)

Table 19: Gender specific Prevalence of PAH in Spain (2017–2030)

Table 20: Total Prevalent Population of PAH in the UK (2017–2030)

Table 21: Sub-type Specific Prevalence of PAH in the UK (2017–2030)

Table 22: Gender specific Prevalence of PAH in the United Kingdom (2017–2030)

Table 23: Total Prevalent Population of PAH in Japan (2017–2030)

Table 24: Sub-type Specific Prevalence of PAH in Japan (2017–2030)

Table 25: Gender specific Prevalence of PAH in Japan (2017–2030)

Table 26: Recommendations for efficacy of drug monotherapy for PAH (group 1) according to WHO functional class.

Table 27: Recommendations for efficacy of initial drug combination therapy for PAH (group 1) according to WHO functional class

Table 28: Recommendations for efficacy of sequential drug combination therapy for PAH (group 1) according to WHO functional class

Table 29: Organizations contributing toward Pulmonary Arterial Hypertension

Table 30: Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence

Table 31: Marketed Drugs developed by United Therapeutics Corporation

Table 32: Marketed Drugs developed by Johnson & Johnson

Table 33: Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences Inc.

Table 34: Marketed Drugs developed by Bayer (AG)

Table 35: Marketed Drugs developed by Pfizer

Table 36: Safety and Efficacy of Marketed Drugs

Table 37: Aurora-GT, Clinical Trial Description, 2020

Table 38: Ralinepag, Clinical Trial Description, 2020

Table 39: LIQ-861, Clinical Trial Description, 2020

Table 40: Bardoxolone Methyl, Clinical Trial Description, 2020

Table 41: Rodatristat Ethyl, Clinical Trial Description, 2020

Table 42: ACE-011, Clinical Trial Description, 2020

Table 43: PB1064, Clinical Trial Description, 2020

Table 44: PB1064, Clinical Trial Description, 2020

Table 45: iNO, Clinical Trial Description, 2020

Table 46: RT234, Clinical Trial Description, 2020

Table 47: 7 Major Market Size of PAH in USD Million (2017–2030)

Table 48: The US Market size of PAH in USD Million (2017–2030)

Table 49: The US market size of PAH by Therapies in USD Million (2017–2030)

Table 50: Germany Market size of PAH in USD Million (2017–2030)

Table 51: Germany market size of PAH by Therapies in USD Million (2017–2030)

Table 52: France Market size of PAH in USD Million (2017–2030)

Table 53: France market size of PAH by Therapies in USD Million (2017–2030)

Table 54: Italy Market size of PAH in USD Million (2017–2030)

Table 55: Italy market size of PAH by Therapies in USD Million (2017–2030)

Table 56: Spain Market size of PAH in USD Million (2017–2030)

Table 57: Spain market size of PAH by Therapies in USD Million (2017–2030)

Table 58: The UK Market size of PAH in USD Million (2017–2030)

Table 59: The UK market size of PAH by Therapies in USD Million (2017–2030)

Table 60: Japan Market size of PAH in USD Million (2017–2030)

Table 61: Japan market size of PAH by Therapies in USD Million (2017–2030)

List of Figures:

Figure 1 : 7MM Pulmonary Arterial Hypertension (PAH) Epidemiology (2017-2030)

Figure 2 : 7MM Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Pulmonary Arterial Hypertension (PAH) Epidemiology in the United States (2017-2030)

Figure 4 : Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Pulmonary Arterial Hypertension (PAH) Epidemiology in Germany (2017-2030)

Figure 6 : Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Pulmonary Arterial Hypertension (PAH) Epidemiology in France (2017-2030)

Figure 8 : Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases in France (2017-2030) 

Figure 9 : Pulmonary Arterial Hypertension (PAH) Epidemiology in Italy (2017-2030)

Figure 10 : Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Pulmonary Arterial Hypertension (PAH) Epidemiology in Spain (2017-2030)

Figure 12 : Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Pulmonary Arterial Hypertension (PAH) Epidemiology in the UK (2017-2030)

Figure 14 : Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Pulmonary Arterial Hypertension (PAH) Epidemiology in Japan (2017-2030)

Figure 16 : Pulmonary Arterial Hypertension (PAH) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

• United Therapeutics Corporation

• Johnson & Johnson

• GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.

• Bayer AG

• Pfizer

• Liquidia Technologies

• Reata Pharmaceuticals

• Altavant Sciences

• Acceleron Pharma

• PhaseBio Pharmaceuticals

• Complexa

• Bellerophon Pulse Technologies

• Respira Therapeutics

  • Tags:
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...
  • Pulmonary Arterial Hypertension (PA...

Forward to Friend

Need A Quote